Received: 13 July 2021
Accepted: 4 February 2022
First Online: 15 February 2022
: This study was approved by an Institutional Review Board (IRB) (“Comité d’Evaluation de l’Ethique des projets de Recherche Biomédicale Paris Nord” (IRB 00006477- of Paris 7 University). Informed consent was waived.
: Not applicable.
: L. Zafrani has received research a grant from Jazz Pharmaceuticals; M. Darmon reports having received grant from MSD, speaker fees from MSD, Astelas and Gilead-Kite and having attended an advisory board for Gilead-Kite. E. Azoulay has received fees for lectures from MSD, Pfizer and Alexion. His institution and research group have received support from Baxter, Jazz Pharma, Fisher&Payckle, Gilead, Alexion and Ablynx. The remaining authors declare having nothing to disclose.